Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%

MT Newswires Live

Sep 13, 2024

Dimerix (ASX:DXB) may receive "commercial incentives" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.

The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.

The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.

Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.

Dimerix shares fell past 4% in recent Friday trade.

Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2467910527"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2467910527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2467910527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467910527","market":"fut","top_or_hot":-1,"title":"Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) may receive \"commercial incentives\" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a Thursday note.</p><p>The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.</p><p>The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.</p><p>Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.</p><p>Dimerix shares fell past 4% in recent Friday trade.</p><p>Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-13 13:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) may receive \"commercial incentives\" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a Thursday note.</p><p>The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.</p><p>The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.</p><p>Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.</p><p>Dimerix shares fell past 4% in recent Friday trade.</p><p>Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4125","symbol_name":"广播","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467910527","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467910527","pubTimestamp":1726205037,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  may receive \"commercial incentives\" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.Dimerix shares fell past 4% in recent Friday trade.Price : $0.42, Change: $-0.02, Percent Change: -4.14%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4125":"广播","BK7501":"新冠治疗股","DXB.AU":"DIMERIX LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，如果针对儿科患者的扩大肾脏疾病试验成功，Dimerix将获得“商业激励”；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9,"AUD":1},"content_text":"Dimerix (ASX:DXB) may receive \"commercial incentives\" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.Dimerix shares fell past 4% in recent Friday trade.Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}